Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Ovid Therapeutics (OVID) over the last 2 years, with Q3 2025 value amounting to $718000.0.

  • Ovid Therapeutics' Current Deferred Revenue changed N/A to $718000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $718000.0, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2020, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Current Deferred Revenue is $718000.0.
  • Ovid Therapeutics' 5-year Current Deferred Revenue high stood at $718000.0 for Q2 2025, and its period low was $718000.0 during Q2 2025.